Replies to post #268222 on Kraig Biocraft Laboratories Inc (KBLB)

[arachnodude]

Potential, projections, and/or expectations are not "blatant lies." They are what they are. The attempt at production revealed a need to recalibrate. What might be acceptable production levels for some, obviously are not for Mr. T. Thankfully!

Let me help you in your future "blatant lie" analyses. Especially for companies in development. Of once-in-a-lifetime, Holy Grail technologies, never brought to market before:

Cautionary Statement Regarding Forward-Looking Information:

Statements made about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

[DimesForShares]

WebSlinger, thanks for the date and the full quote:

"Jan. 18, 2022 - 2022 is positioned to be a breakout year for the commercial sales of Dragon Silk and our broader recombinant spider silk technologies.”"

I suppose the question is: should investors have expected 2022 to be the year that KBLB had production, sales, and revenues given his statement.

To my way of thinking, that expectation was completely justified by his quote.